Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Status:
Enrolling by invitation
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to
evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of
multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1
(DM1) patients